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Acute Pericarditis and Cancer Risk: A Matched Cohort Study Using
Linked UK Primary and Secondary Care Data
Kirstine Kobberøe Søgaard, PhD; Henrik Toft Sørensen, DMSc; Liam Smeeth, PhD; Krishnan Bhaskaran, PhD
Background-—We aimed to examine whether acute pericarditis is an indicator of undetected cancer and identify patient-level
factors associated with high cancer risk among patients presenting with pericarditis.
Methods and Results-—A population-based matched cohort study was conducted using primary care data from the UK Clinical
Practice Research Datalink linked to Hospital Episode Statistics. Patients with acute pericarditis (n=6530) were matched to a
comparison cohort (n=26 111) on age, sex, calendar time, and general practice. We estimated cumulative cancer incidences, and
calculated hazard ratios using Cox regression. Effect modiﬁcation by patients’ characteristics and lifestyle factors was examined,
and we ﬁtted a parsimonious model to evaluate absolute excess risk of later cancer among pericarditis patients by key patient-level
factors. We identiﬁed 728 and 1379 incidents of cancer among pericarditis patients and the comparison cohort (median follow-up,
2.8 and 3.5 years). Pericarditis was associated with an elevated subsequent risk of any cancer (hazard ratio=3.03; 95% conﬁdence
interval, 2.74–3.36). The association was particularly pronounced 0 to 3 months after pericarditis (hazard ratio=23.56; 95%
conﬁdence interval, 18.00–30.83), but a more-modest association remained thereafter (hazard ratio=1.95; 95% conﬁdence
interval, 1.48–2.57 after 3–12 months, and hazard ratio=1.40; 95% conﬁdence interval, 1.21–1.62 after >12 month). Older
individuals hospitalized with pericarditis and with combinations of obesity and smoking were at the highest excess risk of having a
cancer diagnosis 3 to 12 months later, reaching 4.8%.
Conclusions-—Occult cancers may be going undiagnosed during the acute episode of pericarditis. Patients presenting with
pericarditis and combinations of older age, obesity, smoking, and a need for hospitalization might warrant targeted investigations
for cancer. ( J Am Heart Assoc. 2018;7:e009428. DOI: 10.1161/JAHA.118.009428.)
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P ericarditis is the most common disease of the peri-cardium and involves inﬂammation of the pericardium
with or without pericardial effusion (pericardial exudate).
Clinical presentation is characterized by chest pain, pericar-
dial friction rub, and often with speciﬁc ECG changes. Acute
pericarditis mainly affects the younger population, and it is
usually benign and self-limiting. However, pericarditis with
effusion is a known complication to lung and breast cancer
and has been reported also in patients with hematological
malignancies, primary cardiac tumors, gastrointestinal can-
cer, and urogenital cancer.1,2 The connection may stem from
direct extension of cancer cells from nearby structures or
hematogenous spread of abnormal cancer cells through the
bloodstream.3 The link between pericarditis and cancer
raises the question of whether pericarditis may be a useful
marker of occult cancers and of importance in cancer
detection.
A recent Danish population-based cohort study by mem-
bers of our group showed a high rate of several cancers,
including lung, gastrointestinal tract, and urinary tract
cancers, in addition to lymphoma and leukemia during the
ﬁrst 3 months after the pericarditis diagnosis.4 Of note, an
increased risk was also observed for lung cancer, non-
Hodgkin’s lymphoma, and bladder cancer diagnoses up to
several years after the pericarditis diagnosis. Importantly, the
increased risk of cancer was not conﬁned to patients with
pericardial effusion. These results suggest that a more-
thorough investigation may be warranted in some patients
presenting with acute pericarditis to exclude these cancers,
but conﬁrmation of the observed associations is needed in
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independent data sets before such action might be recom-
mended, and there is a need for data on which patients
groups are most likely to beneﬁt from additional
investigations.
We therefore investigated the association between peri-
carditis and subsequent risk cancer in the United Kingdom. We
also examined whether associations between pericarditis and
cancer were modiﬁed by patient-level factors, and evaluated
absolute excess cancer risk among patients presenting with
pericarditis, according to key patient-level factors.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. This is
because we used secondary data under license and are not
permitted to share these data further.
Study Design and Data Sources
We carried out a population-based matched cohort study
using UK data from the Clinical Practice Research Datalink
(CPRD5) and Hospital Episodes Statistics (HES6) databases.
The CPRD is a collection of anonymized longitudinal patient-
level electronic health records from primary care in the United
Kingdom. Data collection was initiated in 1987 and includes
information on diagnoses, prescriptions, and various lifestyle
characteristics as recorded by general practitioners (eg,
smoking status, alcohol use, weight, and height).5 In the
United Kingdom, more than 98% of the population is
registered with a primary care general practitioner, and the
National Health Service provides for general practitioner
access which is free at the point of use. The CPRD includes
data from more than 600 general practices totaling more than
14 million patients; it is broadly representative of the UK
population in terms of age, sex, and ethnicity.5 Whereas the
diagnoses in CPRD generally have a high validity,7 the validity
of pericarditis speciﬁcally has not yet been examined.
Therefore, to improve the ascertainment of pericarditis, in
addition to cancers and comorbidities, we obtained individ-
ually linked HES data, which contain diagnostic information
from in-patient hospital care.6
Study Population
We identiﬁed all people in the CPRD or HESwith a ﬁrst diagnosis
of acute pericarditis between April 1, 1998 and December 31,
2015, with date of ﬁrst diagnosis of pericarditis being the index
date. Patients were identiﬁed using Read codes and Interna-
tional Classiﬁcation of Diseases, Tenth Revision (ICD-10) codes
indicating acute pericarditis (covering idiopathic pericarditis,
acute infectious pericarditis, pericarditis based on underlying
systemic disease [eg, systemic lupus erythematosus, rheuma-
toid arthritis, or uremia], and pericardial effusion; Table S1). We
identiﬁed a comparison cohort who had no history of
pericarditis preceding the index date, matched 4:1 to the
pericarditis patients by practice, sex, and age (within 3 years)
and under follow-up in the CPRD on the index date of the
matched pericarditis patient. We excluded all people with a
cancer diagnosis before the index date from both groups.
Cancer Outcome
We identiﬁed all cancers through medical codes from the
CPRD medical dictionary related to cancer (mapped to ICD-10
chapter 2 headings in a previous study8), and through ICD-10
codes in the HES, and restricted to ﬁrst occurrence of cancer.
We estimated risk for any cancer combined and for 14
individual cancers; the site-speciﬁc cancer outcomes chosen
for analysis included the most common cancers and was
further informed by ﬁndings from previously published data on
pericarditis and cancer risk.4,9,10
Covariates
We classiﬁed patients based on underlying lifestyle-related
factors, namely tobacco smoking, alcohol use, and obesity.
Clinical Perspective
What Is New?
• Whereas a diagnosis of underlying cancer is not uncommon
during an episode of acute pericarditis, our study demon-
strates that there is a high risk of cancer diagnosis for a
prolonged period (notably 3–12 months and beyond)
following pericarditis, suggesting that occult cancers may
be going undiagnosed during the acute episode.
• Patients presenting with pericarditis and combinations of
older age, obesity, current smoking, and a need for
hospitalization had the highest absolute excess risks of
later cancer and might warrant targeted investigations for
cancer.
• The largest excess cancer incidences in the period 3 to
12 months following pericarditis were for hematological,
colorectal, ovarian, kidney, pancreas, breast, and bladder
cancers.
What Are the Clinical Implications?
• Increasing the awareness that some cancers may be being
missed at the time of pericarditis, and about the patients
and cancer types most affected, may help guide diagnostic
workup and lead on to earlier cancer diagnoses.
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We used body mass index (BMI) calculated directly from
weight and height records (weight/height2) and created 4
categories: underweight (BMI <18.5), normal weight
(BMI=18.5–24.9), overweight (BMI=25.0–29.9), and obesity
(BMI >30), using World Health Organization (WHO) grouping
of overweight and obesity. Details on processing, cleaning,
and representativeness of CPRD BMI data have been
previously described.8,11 We categorized smoking status into
never-smoker, current smoker, and ex-smoker, and similarly
alcohol use into never-use, current use, and ex-use. We
excluded patients with missing data in the lifestyle-related
covariates; to identify any possible selection issues arising
from this approach, we descriptively compared those with
complete versus missing data in terms of other covariates
(Table S2).
For descriptive purposes, we obtained information on
acute myocardial infarction registered close to the index date
(between 30 days before and 7 days after) and retrieved
information on connective tissue disease diagnoses for
patients back to 1987 or start of current up-to-standard
follow-up (whichever came later).
Statistical Analyses
Absolute and relative risks of cancer associated with a
pericarditis diagnosis
We followed all patients from the diagnosis of pericarditis (or
index date for matched comparison patients) until the ﬁrst
occurrence of cancer (ie, the outcome), date of death, transfer
out of the CPRD, or December 31, 2015, whichever came
ﬁrst. We used Kaplan–Meier techniques to compute cumula-
tive incidence of cancer (absolute risks) in the exposed and
unexposed groups. We used Cox regression to compare
cancer risks in patients with pericarditis and controls; we
stratiﬁed by matched set to account for the matching by
practice, sex, age, and calendar date. We did not adjust for
further covariates, such as smoking, because our aim was to
assess the extent to which pericarditis predicted future
cancer risk: we did not hypothesize that pericarditis would
cause later cancer. We computed hazard ratios (HRs) for all
cancers combined and separately, classifying follow-up peri-
ods into 0 to 3 months (including day 90), 3 to 12 months
(including day 365), and >12 months following the pericardi-
tis diagnosis/index date. We also computed HRs according to
whether or not the pericarditis patient was recorded as being
hospitalized with this condition and whether or not the patient
had pericardial effusion.
We then investigated modiﬁcation of the association
between pericarditis and any cancer by sex, age, and lifestyle
factors (categorized as described above) by ﬁtting interaction
terms and carrying out likelihood ratio tests. The stratum-
speciﬁc HR estimates were obtained by multiplying main
effect and interaction terms. We also computed HRs accord-
ing to whether or not the pericarditis patient was recorded as
being hospitalized with this condition and whether or not the
patient had pericardial effusion.
Absolute excess cancer risk after pericarditis by
patient-level factors
Finally, we developed a parsimonious model for absolute
excess cancer risk among pericarditis patients, restricting to
the risk period between 3 and 12 months after pericarditis
diagnosis. The ﬁrst 3 months were excluded because many
cancer diagnoses in the period immediately after pericarditis
may have been incidental ﬁndings from routine clinical
investigations into the pericarditis (eg, by chest x-ray, blood
counts) or be occult cancers successfully identiﬁed during the
acute episode. In contrast, cancers diagnosed in the 3- to 12-
month period were likely diagnosed in a separate episode of
care from the pericarditis and could be a target for earlier
detection at the time of the pericarditis. To identify patient-
level factors associated with absolute excess cancer risk after
pericarditis, a 2-stage modeling process was carried out
based on the methods of relative survival modeling.12 First,
we ﬁtted a Poisson model for incident cancer in the control
group and generated predictions from this model to obtain
expected numbers of cancers in the absence of pericarditis,
within strata deﬁned by the covariates in the model (which
were age at index, sex, smoking status, alcohol use, and BMI);
numbers of excess cancers in the pericarditis group were then
derived within covariate strata by subtracting these expected
numbers from the observed numbers of incident cancers in
each stratum; ﬁnally, a second Poisson model was developed
restricted to the pericarditis group, with the numbers of
excess cancers as the outcome, and beginning with the above
covariates plus hospitalization and pericardial effusion. We
used backward elimination (with P-value threshold of 0.20 for
removal) to reduce the model to a limited number of the most
important factors associated with excess cancer risk. The
ﬁnal model from the backward elimination process was used
to generate expected absolute excess cancer risks in the 3- to
12-month period after pericarditis, for every combination of
factors included in the ﬁnal model.
Sensitivity analyses
In a sensitivity analysis, we excluded patients diagnosed with
pericarditis and cancer on the same date, to make sure they
could not explain the entire excess risk for the ﬁrst follow-up
period.
Statistical analyses were done using the STATA statistical
software package (release 14; StataCorp LP, College Station,
TX). The study was approved by the Independent Scientiﬁc
Advisory Committee for MHRA Database Research (approval
number 16_230RA2), and the London School of Hygiene and
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Tropical Medicine ethics committee (approval number
11964). The need to obtain informed consent from patients
has been waived for observational studies using pseudony-
mized data from the CPRD and HES.
Results
Characteristics
In total, we identiﬁed 6530 patients with incident pericarditis
and a comparison cohort of 26 111 people without pericardi-
tis. Pericarditis patients were identiﬁed in the CPRD (n=2371),
HES (n=3776), or in both registries (n=383). Among the
pericarditis patients, 2397 (37%) were recorded as acute
unclassiﬁed, 355 (5%) acute infectious, 3734 (57%) with
pericardial effusion, and 44 (<1%) uremic or postinfarction
pericarditis, or with underlying autoimmune disease.
Patients and comparison cohort members were followed for
a median of 2.8 (interquartile range, 0.8–5.9) and 3.5 years
(interquartile range, 1.5–6.7), respectively. Table 1 describes
the characteristics of the pericarditis patients and the matched
comparison cohort. Ever smoking, recent myocardial infarc-
tion, and history of connective tissue disease were more
common among pericarditis patients than controls.
Cumulative Cancer Incidences in the Pericarditis
and Control Groups
During complete follow-up, 728 incident cancers were
observed among pericarditis patients, with lung cancer as
the most frequent type (n=175), followed by non-Hodgkin’s
lymphoma (n=53), prostate cancer (n=51), colorectal cancer
(n=50), breast cancer (n=43), and leukemia (n=39; Table 2). A
total of 367 of 728 (50%) of cancers were diagnosed within
the ﬁrst 3 months after pericarditis (of these 247 on the same
date as the pericarditis), 77 were diagnosed during the 3- to
12-month follow-up period, and 284 in 1 or more years
following the episode with pericarditis. The cumulative
absolute risk of any cancer among patients with pericarditis
versus controls was 5.7% versus 0.3% at 3 months, 7.2%
versus 1.2% at 12 months, and 12.2% versus 5.5% at 5 years
(Table 2). Absolute risks in the pericarditis group were highest
for lung cancer at 2.2% after 3 months, 2.3% at 12 months,
and 2.8% at 5 years. Females, patients aged >70 years, and
those with pericardial effusion had the highest 3-month risk of
cancer (Table S3).
Hazard Ratios for Association Between
Pericarditis and Cancer
Patients with pericarditis had a higher risk of any cancer
during complete follow-up (HR=3.03; 95% conﬁdence interval
[CI], 2.74–3.36) compared with their comparators from the
general population. All individual cancers, except for
prostate, were associated with an increased overall cancer
risk, ranging from 2-fold increases in risk for breast,
colorectal, and bladder cancer, to HRs between 6.4 and 7.6
for non-Hodgkin’s lymphoma, leukemia, and lung cancer
(Table 3).
Associations between pericarditis and cancer varied by
time since pericarditis, with an HR of 23.56 (95% CI, 18.00–
30.83) for any cancer in the ﬁrst 3 months, reducing to
Table 1. Descriptive of 6530 Patients With Acute Pericarditis
and a Matched Comparison Cohort of 26 111 People Without
Pericarditis
Pericarditis, N (%)
Comparison
Cohort, N (%)
Men* 3983 (61) 15 925 (61)
Age category, y*
<50 2272 (35) 9088 (35)
50 to 69 2185 (33) 8740 (33)
>70 2073 (32) 8283 (32)
Calendar period*
1998–2003 956 (15) 3821 (16)
2004–2008 1963 (30) 7852 (30)
2009–2011 1574 (24) 6295 (24)
2012–2015 2037 (31) 8143 (31)
Smoking
Nonsmoker 2439 (37) 11 424 (44)
Current smoker 1437 (22) 5055 (19)
Ex-smoker 2491 (38) 8397 (32)
Missing data 163 (3) 1235 (5)
Alcohol
Nonuser 630 (10) 2235 (9)
Current user 4438 (68) 17 757 (68)
Ex-user 658 (10) 2125 (8)
Missing data 804 (12) 3994 (15)
BMI categories
Underweight (<18.5) 191 (3) 448 (2)
Normal weight (18.5–24.9) 2062 (32) 8247 (31)
Overweight (25.0–29.9) 2057 (32) 8327 (32)
Obese (>30) 1408 (22) 5128 (20)
Missing data 812 (12) 3961 (15)
Recent myocardial infarction† 319 (5) 15 (0.1)
Connective tissue disease‡ 412 (6) 751 (3)
BMI indicates body mass index.
*Matching factor.
†
Within 60 days before or 7 days after pericarditis.
‡
Ever before or 7 days after.
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HR=1.95 (95% CI, 1.48–2.57) between 3 and 12 months, and
HR=1.40 (95% CI, 1.21–1.62) 1 or more years after the
pericarditis. Positive associations between pericarditis and
individual cancers were also noted within the ﬁrst 3 months
after the index date for all cancer sites investigated except
bladder cancer, though CIs for the magnitude of the HRs were
wide for some outcomes. HRs dropped markedly within the 3-
to 12-month period for most cancers, though there remained
a 7-fold elevated risk for leukemia; for several other
outcomes, HR point estimates did remain elevated, but CIs
were too wide to be conclusive. One or more years after the
index date, there was evidence of a sustained increased risk
of breast cancer: HR=1.82 (95% CI, 1.17–3.14); leukemia,
HR=2.35 (95% CI, 1.07–5.15); and bladder cancer, HR=2.51
(95% CI, 1.33–4.71).
The HR associated with hospitalized pericarditis was higher
than for pericarditis handled in the primary care setting only
(HR for any cancer=3.38 [95% CI, 3.00–3.80] versus HR=2.26
[95% CI, 1.86–2.76], respectively). We also found that
pericardial effusion was associated with a higher overall HR
than pericarditis without effusion (HR=3.59 [95% CI, 3.18–
4.06] versus HR=2.04 [95% CI, 1.69–2.46]).
Effect Modiﬁcation by Individual-Level Factors
We found that several characteristics clearly modiﬁed cancer
risk (Figure). The association between pericarditis and cancer
risk was larger at younger ages (HR=6.62 [95% CI, 4.76–9.22]
at age <50, and 2.66 [95% CI, 2.29–3.08 at age ≥70 years])
and larger among current smokers (HR=4.22 [95% CI, 3.25–
5.50], compared with 2.65 [95% CI, 2.19–3.21] among
nonsmokers). There was some evidence for a larger associ-
ation with cancer in women than in men, but the direction of
potential interaction by alcohol use and BMI categories was
less clear (Figure).
Absolute Excess Risk of Cancer Diagnosis 3 to 12
Months After Pericarditis
Among pericarditis patients, 77 cancers were diagnosed
in the 3- to 12-month period after diagnosis (Table 3). The
largest absolute excess incidences (per 1000 person-
years) in this period (incidence in pericarditis patients
minus incidence in controls) were for leukemia (0.81),
non-Hodgkin’s lymphoma (0.64), and colorectal (0.55),
ovarian (0.54), kidney (0.35), pancreas (0.29), breast
(0.29), and bladder cancers (0.23). A backward elimina-
tion model selection process to develop a model for the
absolute excess risk of cancer in the 3- to 12-month
period after pericarditis led to a ﬁnal model, including
age, BMI (classiﬁed as obese versus nonobese only,
because the overweight category was not predictive in the
ﬁnal model), current smoking, and hospitalization at the
time of pericarditis. Expected excess risks of cancer by
Table 2. Total Number of Cancers (N) and Cumulative Incidences in Percentage With 95% CI, by Follow-up Periods
Pericarditis Comparison Cohort
N 3 Months 12 Months 5 Years N 3 Months 12 Months 5 Years
Any cancer 728* 5.7 (5.2–6.3) 7.2 (6.5–7.8) 12.2 (11.3–13.3) 1379 0.3 (0.2–0.4) 1.2 (1.1–1.4) 5.5 (5.1–5.9)
Oral 6 0.0 (-)† 0.0 (0.0–0.1) 0.1 (0.0–0.3) 3 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Heart/mediastinum/pleura 7 0.1 (0.0–0.2) 0.1 (0.1–0.2) 0.1 (0.1–0.2) 0 0.0 (. . .)† 0.0 (. . .)† 0.0 (. . .)†
Lung 175 2.2 (1.9–2.6) 2.3 (2.0–2.7) 2.8 (2.4–3.3) 140 0.0 (0.0–0.0) 0.1 (0.1–0.2) 0.6 (0.5–0.7)
Breast 43 0.4 (0.2–0.8) 0.7 (0.4–1.2) 2.4 (1.7–3.4) 115 0.1 (0.1–0.2) 0.3 (0.2–0.5) 1.3 (1.0–1.6)
Ovary 12 0.1 (0.1–0.2) 0.2 (0.1–0.3) 0.2 (0.1–0.3) 21 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.1 (0.1–0.2)
Colorectal 50 0.2 (0.1–0.3) 0.3 (0.2–0.5) 0.9 (0.6–1.2) 145 0.0 (0.0–0.1) 0.2 (0.1–0.2) 0.6 (0.5–0.8)
Pancreas 18 0.1 (0.0–0.2) 0.1 (0.1–0.3) 0.4 (0.2–0.6) 32 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.2 (0.1–0.2)
Kidney 11 0.1 (0.0–0.2) 0.1 (0.1–0.3) 0.2 (0.1–3.3) 16 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.1 (0.0–0.1)
Bladder 25 0.1 (0.0–0.2) 0.1 (0.1–0.3) 0.5 (0.3–0.8) 71 0.0 (0.0–0.1) 0.1 (0.1–0.1) 0.3 (0.2–0.4)
Prostate 51 0.1 (0.0–0.2) 0.2 (0.1–0.4) 1.0 (0.7–1.4) 228 0.0 (0.0–0.1) 0.2 (0.1–0.2) 0.9 (0.8–1.1)
Brain/CNS 9 0.0 (0.0–0.1) 0.1 (0.0–0.2) 0.2 (0.1–0.4) 16 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.1)
Non-Hodgkin’s lymphoma 53 0.6 (0.4–0.8) 0.7 (0.5–0.9) 1.0 (0.8–1.4) 44 0.0 (. . .)† 0.0 (0.0–0.1) 0.2 (0.1–0.3)
Hodgkin’s lymphoma 8 0.0 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.3) 1 0.0 (. . .)† 0.0 (. . .)† 0.0 (0.0–0.0)
Leukemia 39 0.3 (0.2–0.5) 0.4 (0.3–0.6) 0.7 (0.5–1.0) 39 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.2 (0.1–0.2)
CI indicates conﬁdence interval; CNS, central nervous system.
*A total of 728 cancers were diagnosed among pericarditis patients: 0 to 3 months, n=357 (247 on the same date as the pericarditis); 3 to 12 months, n=87; and >12 months, n=284.
†
95% CI not calculated because of 0 events.
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12 months from this model are shown in Table 4 and
ranged from 0.3% (95% CI, 0.1–0.7) in the lowest-risk
subgroup (younger nonobese nonsmoking individuals
diagnosed without hospitalization) to 4.8% (95% CI, 2.2–
10.8) in the highest-risk subgroup (older obese current
smokers hospitalized for pericarditis).
Sensitivity Analysis
A total of 357 patients were diagnosed with cancer within the
ﬁrst 3 months; among these, 307 were diagnosed during ﬁrst
months, and of these, 247 were registered on the same date
as pericarditis. We repeated the main analyses after exclusion
of the 247 patients diagnosed with cancer at the same date.
The HR for overall cancer during complete follow-up was 1.92
(95% CI, 1.71–2.15), and for the ﬁrst 3 months, HR was 7.70
(95% CI, 5.65–10.49); though attenuated, the results were
robust and the overall conclusion unchanged.
Discussion
Key Findings
In this study, we found that pericarditis may be a marker of
occult cancer. Patients with pericarditis were at a 3-fold
increased risk of a cancer diagnosis compared with people
from the matched comparison cohort. The most marked
increase in risk was in the ﬁrst 3 months after pericarditis,
likely reﬂecting cancers diagnosed during the episode of care
in which the pericarditis was recorded. However, even after
the ﬁrst 3 months, we found a substantially elevated risk of
cancer in the pericarditis group, indicating that the pericardi-
tis diagnoses may, in some cases, have been a missed
opportunity for earlier cancer diagnosis during the acute
episode. In relative terms, pericarditis was associated with a
particularly elevated risk of cancer in people aged <50 years
and in current smokers, but our model for absolute excess
cancer risks suggested that the greatest opportunity for early
cancer detection may be among older people, obese people,
current smokers, and those hospitalized at the time of
pericarditis.
Comparison With Previous Studies
A recent Danish population-based cohort study including
13 759 patients with acute pericarditis (hospital-based diag-
nosis) examined the risk of subsequent cancer in patients
with no previous cancer history.4 In our present study using
data from the CPRD and HES, we conﬁrmed the key ﬁndings
from the study on the Danish population in a different setting,
Table 3. Hazard Ratios* (HR) of Cancer Among 6530 Patients With Pericarditis and a Matched Comparison Cohort of 26 111
People Without Pericarditis
No. of Cancer Among Pericarditis Patients/Controls, HRs* (95% CI)
n Complete Follow-up n 0 to 3 Months n 3 to 12 Months N >12 Months
Any cancer 728/1379 3.0 (2.7–3.4) 367/77 23.6 (18.0–30.8) 77/213 2.0 (1.5–2.6) 284/1089 1.4 (1.2–1.6)
Oral 6/3 7.0 (1.7–28.3) 0/1 † 1/1 † 5/1 †
Heart/mediastinum/pleura 7/0 >27.1‡ 6/0 † 1/0 † 0/0 †
Lung 175/140 7.6 (5.9–9.9) 143/4 190 (60.8–598) 5/25 1.1 (0.4–2.9) 27/111 1.2 (0.8–2.0)
Breast 43/115 2.2 (1.5–3.3) 10/10 5.00 (2.0–12.7) 6/21 1.7 (0.6–4.4) 27/81 1.9 (1.2–3.1)
Ovary 12/21 3.5 (1.6–8.0) 8/1 32.0 (4.0–255) 3/1 11.2 (1.2–108) 1/19 0.3 (0.0–2.2)
Colorectal 50/145 1.7 (1.2–2.4) 11/11 4.8 (2.0–11.5) 8/24 2.0 (0.8–4.6) 31/110 1.3 (0.9–2.1)
Pancreas 18/32 3.2 (1.6–3.4) 5/1 20.0 (2.4–171) 3/7 3.0 (0.7–13.4) 10/24 2.0 (0.8–5.0)
Kidney 11/16 3.3 (1.5–7.5) 5/2 10.0 (1.4–51.4) 2/1 8.0 (0.7–88.2) 4/13 1.5 (0.5–4.8)
Bladder 25/71 2.2 (1.3–3.7) 3/10 1.3 (0.4–4.3) 4/13 2.2 (0.7–7.6) 18/48 2.5 (1.3–4.7)
Prostate 51/228 1.2 (0.8–1.6) 6/8 4.3 (1.3–14.4) 7/31 1.0 (0.4–2.3) 38/189 1.1 (0.7–1.6)
Brain/CNS 9/16 2.4 (1.0–5.9) 2/1 † 1/1 † 6/14 †
Non-Hodgkin’s lymphoma 53/44 6.4 (4.1–10.1) 37/0 >148‡ 5/8 2.3 (0.8–7.2) 11/36 1.6 (0.8–3.3)
Hodgkin’s lymphoma 8/1 31.1 (3.9–248) 7/0 † 0/0 † 1/1 †
Leukemia 39/39 7.0 (4.0–12.4) 20/2 80.0 (10.7–596) 5/4 6.7 (1.6–27.9) 14/33 2.4 (1.1–5.2)
Person-time at risk: pericarditis patients: 25 593, comparison cohort: 117 655. CI indicates conﬁdence interval; CNS, central nervous system.
*Adjusting for matching factors by design (age [3 years], sex, and practice).
†
Not estimated because of limited number of events.
‡
There were 0 events in the comparison cohort; therefore, we added 1 event to the comparison cohort to give a lower bound for HR.
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including the highly elevated risk of a cancer diagnosis within
the ﬁrst 3 months, decreasing thereafter. Importantly, we
have also built on these ﬁndings and added to their clinical
relevance by identifying patient groups who may be at highest
risk of missed cancers and warrant targeted investigations at
the time of pericarditis. Some important differences between
the 2 studies should be noted. The Danish cohort were
younger than our cohort (median age was 49 versus
60 years) and had a longer follow-up (median of 6.4 versus
2.8 years). The prevalence of recent myocardial infarction and
connective tissue disease were comparable. In the Danish
cohort, overall relative risk of cancer associated with
pericarditis was 1.5, lower than ours of 3.0. Similarly, in the
ﬁrst 3 months, relative risk estimates were smaller in the
Danish study (12- versus 24-fold increase). In regard to
cancer-speciﬁc relative risks, there was agreement in
direction and size for colon, bladder, and prostate, whereas
the estimates were substantially higher for oral, lung, breast,
pancreatic, kidney, and ovary, as well as lymphoma and
leukemia in the UK cohort. In both cohorts, relative risks in
the follow-up period beyond 1 year remained clearly elevated
for oral cancer and bladder cancer, and results were in
agreement also for lung, colon, ovary, kidney, and prostate
cancer as well as non-Hodgkin’s lymphoma, though for
several cancers, including lung cancer, the present study
did not have sufﬁcient power to rule out that the modest
observed association was attributable to chance given that
the CI included unity. By contrast, in the Danish cohort, there
was no excess occurrence of breast cancer and leukemia
beyond 1 year of follow-up, whereas the HR of these cancers
remained >2-fold elevated in the UK cohort. Consistent with
the Danish study, we conﬁrmed that the increased risk of
Figure. HRs stratiﬁed by characteristic and lifestyle factors. HRs adjusted for matching factors by design
(age, sex, practice, and calendar period). Likelihood ratio test for interaction: sex, P=0.03; age category,
P<0.001; smoking status, P=0.006; alcohol use, P=0.03; body mass index, P=0.02. BMI indicates body
mass index; CI, conﬁdence interval; HR, hazard ratio.
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cancer was not conﬁned to pericarditis patients with a record
of pericardial effusion, and that the relative risk of cancer was
higher in women than men. Differences between the 2 studies
may be explained by a number of things. Differences in
distribution of patient characteristics (eg, age and smoking) in
addition to length of follow-up may have impacted on the
results. Also, for some cancers, incidence rates may be
different in the United Kingdom and Denmark. This would
impact on both the cancer-speciﬁc as well as the overall HR.
Finally, there could be differences in recording practices
between the United Kingdom and Denmark.
Strengths and Limitations
The diagnosis of acute pericarditis is based on 2 of the
following criteria: (1) chest pain, (2) pericardial friction-rub,
(3) characteristic ECG changes, and (4) pericardial effusion on
2-dimensional echocardiography. Elevated inﬂammatory
markers and evidence of inﬂammation by imaging modalities
may support diagnosis. The diagnosis can be challenging
given that the only reliable criterion may be symptomatic
chest pain, whereas criteria 2 to 4 can be difﬁcult to conﬁrm
with the standard diagnostic workup in the general practi-
tioner setting. In the hospital setting, cardiac magnetic
resonance imaging has a high sensitivity for detecting even
smaller pericardial effusions. Our cohort was based on data
from the CPRD and HES, which are considered to have a good
generalizability both to the UK population and to comparable
countries. Pericarditis diagnoses, as recorded in the CPRD
and HES, have not been speciﬁcally validated, so there may
have been some misclassiﬁcation in our exposure measure,
but our combined use of primary care and hospital data
should have improved sensitivity and allowed us to include
patients who may have had pericarditis without hospital
admission.
More broadly, CPRD diagnosis data have been shown to
have good validity, including for cancer diagnoses, which have
a high concordance with data from other sources.7 The large
size of the CPRD gave us power to investigate site-speciﬁc
cancers and stratify by time since pericarditis. Even in this
large database, though, some results for site-speciﬁc cancers
had limited precision because of few events, particularly when
we also stratiﬁed by time since pericarditis.
We aimed to examine whether pericarditis was a marker of
prevalent undiagnosed cancer and therefore excluded all
patients known to have cancer at the time of pericarditis
diagnosis. Still, for some patients, admission for pericarditis
may have prompted more-thorough workup leading to cancer
diagnosis, most evidently inﬂuencing the ﬁrst follow-up period
(3 months). In particular, patients were likely examined with a
chest x-ray or other imaging, which could have revealed a
previously unrecognized lung cancer or lymphoma, even if the
pericarditis itself was not related to the cancer. Relative risk
of cancer may thus be inﬂated during the ﬁrst follow-up
period. Nevertheless, the ﬁnding of an increased risk for a
number of cancer sites more than 3 months, and sometimes
more than 12 months, after the acute pericarditis episode
suggests that this incidental identiﬁcation of cancers during
pericarditis workup cannot explain all of the observed
associations. In developing our ﬁnal model for absolute
excess cancer risk among the pericarditis group, we dealt
with this issue by excluding the ﬁrst 3 months of follow-up to
reduce the inﬂuence of cancers that may have been incidental
ﬁndings unrelated to the pericarditis, and for which there
would in any case have been little opportunity for earlier
detection.
Clinical and Public Health Implications
The majority of patients with pericarditis will have a self-
limiting disease and will mainly only undergo workup aiming
to exclude myocardial infarction (ie, ECG, echocardiography,
biomarkers for acute cardiac ischemia, or chest x-ray).9
According to guidelines, patients diagnosed in more-recent
years also should have assessment of markers of inﬂamma-
tion (ie, C-reactive protein and/or erythrocyte sedimentation
rate), white blood cell count with differential count, renal
function, and liver tests).9 Additional testing with imaging
examination is indicated in high-risk patients deﬁned by the
Table 4. Absolute Excess Risk of Cancer in the 3- to 12-
Month Period After Pericarditis, by Key Covariates
Excess risk in % (95% CI)
Age <50 y Age 50 to 69 y Age >70 y
Not hospitalized
Not obese,
nonsmoker
0.3 (0.1–0.7) 0.8 (0.4–1.6) 1.2 (0.6–2.4)
Not obese,
smoker
0.5 (0.2–1.1) 1.3 (0.6–2.9) 2.0 (0.9–4.7)
Obese,
nonsmoker
0.5 (0.2–1.2) 1.3 (0.7–2.7) 2.0 (0.9–4.4)
Obese, smoker 0.7 (0.3–2.0) 2.2 (0.9–5.1) 3.3 (1.3–8.6)
Hospitalized
Not obese,
nonsmoker
0.4 (0.2–1.0) 1.2 (0.7–2.1) 1.8 (1.2–2.8)
Not obese,
smoker
0.7 (0.3–1.6) 2.0 (1.0–3.9) 3.0 (1.5–5.9)
Obese,
nonsmoker
0.7 (0.3–1.7) 2.0 (1.1–3.5) 3.0 (1.7–5.2)
Obese, smoker 1.1 (0.4–2.8) 3.2 (1.6–6.7) 4.8 (2.2–10.8)
Analysis restricted to people cancer free at 3 months after pericarditis. CI indicates
conﬁdence interval.
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presence of clinical indicators (eg, large pericardial effusion).
It is clinically important to know whether patients presenting
with ﬁrst-time pericarditis should be investigated more
thoroughly to exclude particular cancers. The National
Institute for Health and Care Excellence (NICE) guideline
proposed a 3% positive predictive value threshold for markers
of cancer, meaning that in cases where speciﬁc markers are
associated with a >3% risk of cancer, the patient should follow
the recommendations for “suspected cancer pathway
referrals.”13 In our cohort, several subgroups of older people
with combinations of obesity, current smoking, and hospital-
ization for pericarditis had absolute excess cancer risks of
>3% in the 3- to 12-month period following pericarditis and
thus may warrant referral and investigations to speciﬁcally
exclude cancer. The largest excess incidences in this period
were for hematological malignancies (in particular, non-
Hodgkin’s lymphoma and leukemia) and colorectal, ovarian,
kidney, pancreas, breast, and bladder cancers; hence, these
would appear the most important cancers to exclude following
a diagnosis of pericarditis. This would clearly result in
economic and clinical costs, but these may be more than
offset by the gains of earlier detection14; a formal study of
cost-beneﬁt in this scenario may be informative.
Conclusion
We conﬁrmed that pericarditis may signal an undetected
cancer. Although substantial numbers of cancers are diag-
nosed during the acute pericarditis episode, our ﬁndings of
prolonged increased risks of some types of cancer strongly
suggest that many occult cancers may be going undiagnosed
during the acute episode. Older people, obese people, current
smokers, and those hospitalized at the time of pericarditis
were at particularly high absolute excess risks of later
cancers, and the presence of combinations of these risk
factors in a patient presenting with pericarditis may indicate a
need for referral or investigations to exclude cancer.
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Table S1. Codes indicating acute pericarditis in the Clinical Practice Research Datalink and 
in the Hospital Episodes Statistics. 
 
 
 
Clinical Practice Research Datalink Hospital Episodes Statistics 
Medcode Readterm ICD-10 code 
   
 Acute pericarditis, idiopathic I30.0; I30.8; I30.9 
3399 Acute pericarditis  
14646 Other and unspecified acute pericarditis  
27606 Acute pericarditis – unspecified  
100907 [X]Other forms of acute pericarditis  
36755 Acute pericarditis NOS  
15089 Acute pericarditis in diseases EC NOS  
29551 Acute pericarditis in diseases EC  
108258 [X]Pericarditis in other diseases classified elsewhere  
5690 [X]Pericarditis in other diseases classified elsewhere  
   
 Acute infectious pericarditis I30.1; I32.0; I32.1 
8411 Viral pericarditis NOS  
9113 Coxsackie pericarditis  
16803  Meningococcal pericarditis  
16996 TB - acute pericarditis  
36496 Acute pericarditis – pneumococcal  
57126 Acute pericarditis – tuberculous  
59102 Acute idiopathic pericarditis  
64481 Acute purulent pericarditis unspecified  
65897 Syphilitic pericarditis  
104081 Acute pericarditis – staphylococcal  
   
 Pericardial effusion I31.3 
2520 Pericardial effusion – acute  
18293 Pericardial effusion – noninflammatory  
45311 Pericardial effusion – acute  
105192 Pericardial effusion  
   
 Pericarditis, disease elsewhere classified I32.8  
11920 Systemic lupus erythematosus with pericarditis  
40956 Acute pericarditis – uraemic  
35119 Post infarction pericarditis  
 Rheumatoid arthritis  
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Table S2. Descriptive for 6,337 patients with and 26,304 patients without missing data. 
 
 With missing data              Without missing data 
Men 4533 (72) 15,375 (58) 
Median age, years (IQR)    39 (22-63) 63 (48-75) 
Median follow-up, years (IQR)    2.9 (1.2-5.9) 3.5 (1.4-6.7) 
Recent myocardial infarction* 
Connective tissue disease† 
128 (2.0) 
133 (1.7) 
1035 (3.9) 
884 (3.1) 
* Within 60 days before or 7 days after pericarditis 
† Ever before or 7 days after 
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Table S3. Cumulative incidence of any cancer at 3 months, by characteristics. 
 
 Cumulative incidence % (95% CI) 
 
Pericarditis patients Comparison cohort 
All patients 5.7 (5.2-6.3) 0.3 (0.2-0.4) 
Pericardial effusion 9.1 (8.2-10.1) NA 
Men 4.5 (3.9-5.2) 2.4 (1.8-3.4) 
Women 7.6 (6.6-8.7) 3.9 (2.9-5.3) 
Age <50 years 2.7 (2.1-3.5) 0.0 (0.0-0.1) 
Age 50-69 years 6.8 (5.9-8.0) 0.2 (0.2-0.4) 
Age >70 years 7.8 (6.8-9.1) 0.7 (0.5-0.9) 
Recent myocardial infarction* 0.7 (0.2-2.6) NA 
Connective tissue disease† 4.9 (3.1-7.5) 1.0 (0.5-2.0) 
Current smoker 7.4 (6.2-8.9) 0.2 (0.1-0.4) 
Current user of alcohol  5.5 (4.8-6.2) 0.3 (0.2-0.4) 
Underweight (<18.5) 8.6 (5.3-13.6) 0.5 (0.1-1.8) 
Normal weight (18.5-24.9) 6.2 (5.2-7.3) 0.3 (0.2-0.4) 
Overweight (25-29.9) 5.2 (4.3-6.3) 0.3 (0.2-0.5) 
Obese (>30) 5.5 (3.6-5.8) 0.4 (0.3-0.6) 
 
* Within 60 days before or 7 days after pericarditis. † Ever before or 7 days after 
NA, not applicable 
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